Faeth Therapeutics is hosting a virtual KOL event on Tuesday, October 6, at 10 am ET featuring Marcus Goncalves, MD, PhD, to discuss the PAM pathway in human cancer and the company's upcoming Phase 2 readout in endometrial cancer.

Faeth Therapeutics is a clinical-stage biotechnology company pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway, one of the most frequently altered oncogenic pathways in cancer. Our lead program, PIKTOR, is an investigational all-oral combination designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously. We are advancing a pipeline of therapies with the goal of improving outcomes for patients with some of the most challenging cancers.